BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asai A, Asano T, Ogawa C, Abe H, Hotta N, Shima T, Iio E, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Hidaka I, Moriya A, Tsuji K, Akahane T, Yamashita N, Okubo T, Arai T, Morita K, Kawata K, Tanaka Y, Okanoue T, Maeda S, Kumada T, Iwakiri K; KTK49 Liver Study Group. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infect Dis Ther 2020;9:851-66. [DOI: 10.1007/s40121-020-00329-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
2 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Reference Citation Analysis]
3 Kaba A, Yamanaga S, Hidaka Y, Toyoda M, Kashima M, Takekuma Y, Inadome A, Yokomizo H, Miyata A. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report. Transplant Proc 2022:S0041-1345(21)00950-7. [PMID: 35120765 DOI: 10.1016/j.transproceed.2021.12.028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. Glob Health Med 2021;3:321-34. [PMID: 34782876 DOI: 10.35772/ghm.2021.01083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group. Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res 2021. [PMID: 34861090 DOI: 10.1111/hepr.13739] [Reference Citation Analysis]
6 Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, Toyoda H, Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, Ikegami T, Abe H, Matsuura K, Tanaka Y, Tsubota A. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. Hepatol Commun 2022. [PMID: 35344290 DOI: 10.1002/hep4.1941] [Reference Citation Analysis]
7 Murayama A, Tajiri K, Kanegane C, Murakami J, Hayashi Y, Yasuda I. Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia. Case Rep Gastroenterol 2021;15:729-35. [PMID: 34594173 DOI: 10.1159/000518306] [Reference Citation Analysis]